You'd better be
BEARISH SITTING DUCK BULLISH
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets.
Discount: 41%
Average yearly return: 47%
Yield: N/A
Outperformer
On January 25, 2017:
Clovis Oncology had its target price hoisted by equities researchers at Stifel Nicolaus from $52.00 to $86.00. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.
Clovis Oncology had its target price hoisted by equities researchers at Stifel Nicolaus from $52.00 to $86.00. The firm presently has a “buy” rating on the biopharmaceutical company’s stock.
No comments:
Post a Comment